Conferences - Results from #460

Viewing 461-480 of 11531 articles

APCCC 2024: High-Risk and Locally Advanced Prostate Cancer in the Context of Current Diagnostic and Therapeutic Options – Which Is the Ideal Definition to Use for Clinical Practice?

APCCC 2024: Regional Lymph Node Staging for High-Risk and Locally Advanced Prostate Cancer – What Should Be the Standard?

APCCC 2024: Is Digital Rectal Examination for Definition of Local T-Stage Still Appropriate in the Time of MRI and Next-Generation Imaging?

EAU 2024: PSA Persistence After Radical Prostatectomy: Optimal Treatment in the Case of PSA Persistence

EAU 2024: Is All PSA Persistence Created Equal? Definition and Diagnostic Work-Up

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What to Test Before Start of Hormonal Treatment and What to Monitor

EAU 2024: High-Risk Biochemical Recurrence After Radical Prostatectomy and Negative PSMA PET: What to Do? Systemic Therapy Alone

EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response

EAU 2024: High-Risk Biochemical Recurrence after Radical Prostatectomy and Negative PSMA PET: What to Do? The Guideline’s View

EAU 2024: First-Line Maintenance Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in Routine Care in Germany: Preliminary Results of the Prospective CARAT-UBC Registry

EAU 2024: State-of-the-Art Lecture: Local Therapy in mHSPC: Who Does Really Benefit?

EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? Yes, the More the Merrier

EAU 2024: TiP: Phase 3 Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

EAU 2024: Moving Towards Intensified Treatment Paradigms in First Line Metastatic Kidney Cancer: Triplet Combinations at Any Cost - Is More Always Better? No, Less Is More

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? Yes, We Can

EAU 2024: Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment

EAU 2024: State-of-the-Art Lecture: Clinical and Molecular Stratification of Men with Biochemical Recurrence After Radical Prostatectomy

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? No, We Cannot

EAU 2024: Pelvic Lymph Node Dissection in Prostate Cancer: Update of the Limited vs. Extended Randomized Clinical Trial

EAU 2024: State-of-the-Art Lecture: How to Personalize Treatment in mHSPC? More than Just Counting Metastases

19
20
21
22
23
24
25
26
27
28